We have previously established that the tissue-specific activity of the hepatitis B virus (HBV) enhancer is mediated by trans-acting cellular factors. Here we have studied in vitro the interactions between the HBV enhancer DNA and cellular factors present in nuclear extracts from both liver and nonliver cell types. The results presented in this study imply the involvement of several distinct, ubiquitous, and liver-specific cellular factors with the HBV enhancer. Sequence analysis of the binding sites for these proteins on HBV DNA showed homologies to sequence motifs known to bind other previously characterized and purified transcription factors including CAAT/enhancer-binding protein. Thus, all of these binding sites may function in concert to activate liver-specific transcription of HBV genes from their respective promoters.
Human hepatitis B virus (HBV), a member of the Hepadnaviridae family, is a small DNA virus that exhibits marked liver tropism (for reviews, see references 11 and 29) . Such hepatotropic expression may be due to preferential attachment and entry into hepatocytes, liver-specific viral regulatory elements, or both. One such HBV regulatory element that has generated interest is the viral enhancer (37, 40) . Transcriptional enhancers, including the HBV element, are cis-acting regions of DNA that can potentiate transcription from autologous and heterologous promoters in a relatively position-and orientation-independent manner (16, 37, 40) . The HBV enhancer element is strategically placed (Fig. 1A) 3' to the surface antigen gene and 5' to the core and X antigen genes and is included in the coding frame of the putative polymerase gene. Such a location makes it plausible for the enhancer to modulate activity of the core and X promoters located downstream and the surface antigen promoter(s) located upstream. Requirement of the enhancer for efficient expression of S antigen and X genes has been previously demonstrated (2, 16, 38) . Furthermore, it is the only enhancer, to our knowledge, whose sequences are part of mature transcripts, in this case the 2.1-kilobase surface antigen mRNA and the 3.5-kilobase RNA species including the pregenomic RNA (for a review, see reference 11).
It has been previously shown by means of gene transfer experiments that the HBV enhancer exhibits cell type specificity for human hepatoma cells and that this specificity is due to trans-acting factors (16, 37) . There is substantial evidence for the involvement of a variety of proteins in the regulation of transcription (12, 20, 28, 32, 39) . The binding sites for such trans-acting protein factors have been mapped on a number of viral and cellular enhancers (3, 29, (32) (33) (34) (35) 41) . It is now becoming increasingly evident that the enhancer-mediated transcriptional activation and tissue specificity involve interactions between conserved sequence motifs on the DNA and closely related cellular factors. The mechanisms for such a regulatory control, however, have * Corresponding author. t Present address: UNIDO International Center for Genetic Engineering and Biotechnology, New Delhi-110067, India. yet to be established. A cassette-shuffling model has been proposed to explain the substantial overlap seen between various enhancers in terms of sequence motifs and the factors that bind to them (34) .
Because of the host and tissue specificities of the HBV enhancer, we set out to identify and characterize in detail the nature of the protein-DNA interactions between trans-acting cellular factors and the HBV enhancer element. Using DNase I protection analysis, we define here the binding sites of both liver-specific and ubiquitous factors on the enhancer element and discuss their possible significance in HBV gene expression.
MATERIALS AND METHODS
Cell lines and extracts. and HepG2, human hepatoma cell lines that are negative for HBV sequences, and HeLa, a human cervical carcinoma cell line, were used. Nuclear extracts were prepared from HeLa, Huh-7, rat liver, and spleen tissues. Cultured cell lines were grown in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum and antibiotics (75 U of penicillin and 50 mg of streptomycin per ml). Nuclear extracts from HeLa and Huh-7 cells were prepared by the method of Dignam et al. (7) . Extraction of nuclear proteins from rat liver and spleen was carried out by the method of Johnson et al. (18) . Protein concentrations were determined by using the Bio-Rad protein assay kit and were typically between 3 and 12 mg/ml. Extracts were stored at -70°C. Luciferase assays were carried out by the method of de Wet et al. (6) . Cell transfections were by the CaPO4 method (14) . Plasmid pSV2CAT (13) was used as a control plasmid to normalize the transfection values for the differential uptake by different cell lines. Methods of isolation, propagation, and immortalization of rat primary hepatocytes to generate cell line CWSV1 have been previously described (42) . Plasmids NaCl, 0.03 M EDTA, 1% sodium dodecyl sulfate, 100 ,ug of tRNA per ml). The samples were extracted once with phenol-chloroform, and the aqueous phase was precipitated with ethanol. The pellets were dried and suspended in 8 of loading buffer (0.1 M NaOH-formamide [1:2, vol/vol], 0.1% xylene cyanol, 0.1% bromophenol blue). After heating for 5 min at 100°C, 4 pI of each sample was subjected to electrophoresis, as described earlier. Marker sequencing ladders were generated by using homologous fragments by the method of Maxam and Gilbert (23) .
For footprint competition, a 50-to 100-fold molar excess of either homologous or heterologous fragments or oligonucleotides was mixed with the corresponding HBV enhancer probe fragments and incubated with rat liver nuclear extract (RLNE).
RESULTS
The HBV enhancer has been previously mapped on the genome from nt 966 to 1308 (37, 40) . To compare the activities of the HBV enhancer among the various liver and nonliver cells, we used the firefly luciferase reporter gene in a transient scheme of expression (6) . The luciferase gene (luc) expression plasmids ( Fig. 1B) and enhancer sequences contained either the simian virus 40 (SV40) early promoter (41) (pEnS41uc) or the HBV core gene promoter (pABluc). The relative levels of induction of luc gene activity in the liver-derived cell lines (Huh-7, HepG2, and rat hepatocytes) and nonliver HeLa cells are shown in Fig. 1B . The levels of induction of luciferase activity with fragment A ranged from 30-to 70-fold above the values obtained with either the luciferase expression plasmid pSV232luc (with the enhancerless SV40 early promoter) (6) or pABluc (the HBV core and pregenomic promoter) in liver-derived cell lines but were only fivefold greater in HeLa, establishing its cell typespecific enhancer activity. The luc activity with fragment B showed approximately similar levels of stimulation, whereas fragment C was insufficient for full enhancer activity (Fig,  1B) . These data are in agreement with data from previous studies from this and other laboratories (1, 16, 37) . All transfection experiments include an independent plasmid containing an SV40-driven chloramphenicol acetyltransferase (13) gene that was used to monitor transfection efficiency (data not presented). Of interest in the present study is the demonstration of enhancer function in CWSV1, a cell line derived from rat hepatocytes that have been immortalized by SV40 T antigen (42 The footprint analysis of fragment B (AccI-HpaII, nt 1074 to 1308) incubated with nuclear extracts prepared from HeLa, Huh-7, and RLNE is shown in Fig. 2 . At least four distinct footprints, designated FP-I to FP-IV, were observed within the HBV enhancer fragment B on the coding (Fig. 2) as well as on the noncoding (data not shown) strand with all the extracts used. An additional footprint, FP-V, was also observed only in the presence of RLNE extract (Fig. 2C ). This footprint, however, was weak with Huh-7 extracts. Thus it is difficult at this time to suggest that this interaction is liver specific. The nucleotide sequence of each of these protected regions and its relative position on the HBV enhancer element are summarized in Fig. 6 (Fig. 3A) . FP-VI is protected between nucleotide positions 1017 and 1045, FP-VII is protected between nt 993 and 1009, and FP-VIII is protected between nt 971 and 991. Each region of protection was again flanked by hypersensitive sites. Interestingly, with the Huh-7 extract (Fig. 3B) , the protected region of FP-VI contained several internal hypersensitive sites compared with the FP-VI of RLNE (Fig. 3C) (Fig. 4) . Footprints FP-VI to FP-VIII were not observed in the presence of spleen nuclear extracts, thereby reaffirming the liver-specific nature of the factors. The general footprinting patterns with RLNEs are noticeably clear compared with those of human hepatoma cell line extracts, perhaps indicating the abundance of these proteins in tissues compared with their abundance in cell lines (Figs. 2 through 5) .
A sequence analysis of the DNase I-protected regions (FP-I to FP-VIII) within the enhancer element revealed homologies to several known sequence motifs. These are the nuclear factor (NF)-1 binding site (FP-I), the SV40 enhancer core element (FP-II and FP-VI), the polyomavirus enhancer factor EF-C element (FP-III), and the hepatocyte nuclear factor-i (HNF-1) sequence (FP-VI). By using some of the sequences described above as competitors in DNase I protection experiments, we show here that HBV enhancer element may have the same factors as elements found in other enhancers and promoters (Fig. 5) . This is shown by binding competitions with unlabeled oligonucleotide sequences and fragments corresponding to the sequence motifs. While this study attempts to demonstrate that distinct factors may be binding to the various sequences on the HBV enhancer element (by competitions, heat stability, and heparin-Sepharose column chromatography), the identity of the factor(s) specific to the sequence motifs remains to be determined.
A palindrome sequence (5'-TGGCCATAGGCCA-3') in the protected region FP-I (between nt 1223 and 1236) shows considerable homology to the binding site for NF-1. NF-1, a protein originally purified from HeLa cells (30) , has recently been assigned a multifunctional role, i.e., adenovirus DNA replication and transcription (24) . It has recently been shown to be similar to the transcription factor responsible for selective recognition of eucaryotic promoters containing the sequence CCAAT (19) . When we used a multimeric oligomer containing the NF-1 binding site (30), we observed no competition at the FP-I site (Fig. SA) . Further, the inability of HBV enhancer DNA to displace purified NF-1 from its authentic binding site in a competition assay (unpublished results of R. M. Gronostajski, Ontario, Canada, and J. Oikarinen, University of Oulo, Finland) indicated that this sequence, although it shows no binding to the NF-1 protein, may be interacting with an NF-1-like family of proteins (15, 20) . Ben-Levy et al. (1) recently demonstrated that NF-1 does bind to the sequences of this footprint. However, the purification of these sequences was performed by using an affinity column containing an NF-1-like sequence derived from hepatitis B surface antigen promoter region, and that may explain the different results obtained here.
DNA sequences included in FP-II and FP-VI are homologous at 7 and 6 base pairs, respectively, to the 8-base-pair SV40 enhancer core element 5'-GTGGTTTC-3' (19) . This region of protection is effectively displaced by competition with the SV40 enhancer-promoter fragment (Fig. 5B) . A purified liver-specific factor, C/EBP (18) , has recently been shown to bind to this sequence (22) in FP-II and FP-VI. As mentioned earlier, FP-VI also contains the C/EBP binding site, and juxtaposed to this sequence is the sequence with homology to the HNF-1 sequence motif(5). The oligonucleotide containing the HNF-1 binding sequence removes this footprint (Fig. SC) , suggesting that HNF-1 is required for the C/EBP binding. In fact, our recent preliminary data on point mutations in this region also lend support to this notion (N. U. Patel, unpublished data). Another sequence (CTGAC GCA), which is a part of FP-II, has considerable homology to the AP-1/jun binding site (20) . Ben-Levy et al. (1) identified this sequence in the enhancer to be 12-O-tetradecanoylphorbol-13-acetate inducible. Immediately adjacent to FP-II, with an internal hypersensitive site, is FP-III, which bears perfect consensus to the polyomavirus EF-C factorbinding sequence and has been shown to be the target site (NF-1) , and SV40 enhancer sequence PuvII-HindIII (41) (SV ori), an oligomer containing the sequence motif that binds to the protein HNF-1 5'ATTAAC-3' (5) (HNF-1), the unlabeled fragment C (HpaI-AccI) of the HBV enhancer (C), and HpaI-NcoI (nt 966 to 1375) and HpaI-BamHI (nt 966 to 1403) HBV enhancer sequences including the X promoter. Each reaction contained a 100-fold molar excess of unlabeled competitors. Symbols are as defined in the legend to Fig. 2. for this factor (26) . So far, sequence comparisons of footprint regions FP-VII and FP-VIII have not revealed any strong homologies to any previously characterized sequence. Studies are under way to determine the identities of these factors.
DISCUSSION
The tissue-specific activity of the HBV enhancer has been well established by gene transfer methods (16, 37; Fig. 1 trans-acting cellular factors are important for this activity (16, 17, 21, 22, 36) . To define and begin to understand such cellular factors, we have studied in vitro the interactions between various cellular extracts of both liver and nonliver cell origins and the HBV enhancer DNA. We show here by means of DNase I protection (footprinting) analysis that the HBV enhancer DNA contains binding sites for multiple cellular factors, some of which appear to be ubiquitous to all cell types while others are specific to liver cells. Interestingly, in the present analysis with the crude nuclear extracts, the target sites for these liver-specific factors all appear to be restricted to fragment C, while the target sites for ubiquitous factors are restricted to fragment B. However, we have found that fragment B alone is capable of conferring both enhancer and cell-type-specific activity, indicating that the fragment contained all the necessary information for mediating HBV enhancer activity (Fig. 1B ). An 83-base-pair sequence contained within this fragment, which will include our FP-II and FP-III, was recently shown (1) to produce enhancer activity, although at levels lower than those of fragments containing all five footprints. It is entirely possible that some footprints obtained with fragment B result from binding of similar proteins from nonliver extracts (HeLa or spleen tissue), but these interactions do not promote transcription in nonliver cells (Fig. 1B) (16 (Fig. 6 ). This sequence is found in a variety of viral and cellular enhancers (4, 20, 41) and is shown by point mutations and deletion of the entire sequence to be critical for enhancer activity. 
